Log in to save to my catalogue

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is...

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6485034

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

About this item

Full title

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Publisher

New Zealand: Dove Medical Press Limited

Journal title

OncoTargets and therapy, 2019-01, Vol.12, p.2989-2997

Language

English

Formats

Publication information

Publisher

New Zealand: Dove Medical Press Limited

More information

Scope and Contents

Contents

The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains poor, with a median survival of 2-4 years. About 10% of newly diagnosed breast cancer patients present with metastatic disease, and 30%-50% of those diagnosed at earlier stages will subsequently progress to mBC. In terms of ongoing management for advanced/met...

Alternative Titles

Full title

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6485034

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6485034

Other Identifiers

ISSN

1178-6930

E-ISSN

1178-6930

DOI

10.2147/OTT.S189163

How to access this item